The global allergic conjunctivitis market size was estimated to be USD 3.85 billion in 2023 and is expected to reach at USD 7.61 billion by 2034 with a CAGR of 6.39% during the forecast period 2024-2034. Increasing advancements in treatment options, rising demand for over-the-counter (OTC) drugs, growing awareness initiatives by market players, surge in demand for the management of the condition, increasing prevalence of allergic conjunctivitis, escalating demand for healthcare services, rising focus on development of new drugs for allergic conjunctivitis, growing research & development activities, and surge in number of clinical trial procedures are the critical factors fuelling market growth.
Surge in number of clinical trial procedures is predicted to boost the market growth during the forecast period. Allergic conjunctivitis is a condition characterized by eye irritation resulting from an allergic reaction to substances like pollen or mold spores. It is particularly prevalent during the hay fever season when exposure to allergens is heightened. Allergy-related conjunctivitis is a widespread issue, particularly among individuals with allergies. As a result, pharmaceutical companies are prioritizing the development of innovative medications to address this condition. For instance, in July 2022, A groundbreaking therapy, potentially the first of its kind, developed by Aldeyra Therapeutics called Reproxalap, submitted for FDA approval, offering a new approach to treating dry eye disease. Reproxalap is designed to modulate RASP, a novel anti-inflammatory target for dry eye.
By treatment, antihistamines and mast cell stabilizers was the highest revenue-grossing segment in the global allergic conjunctivitis market in 2023 owing to the growing prevalence of allergic conjunctivitis, rising demand for antihistamine eye drops to relieve symptoms in the eyes, and increasing new product launches by market players. Additionally, corticosteroids is predicted to grow at fastest CAGR during the forecast period owing to the surge in research & development activities and rising approvals by regulatory bodies. For instance, in May 2022, Dextenza, also known as the dexamethasone punctal insert, has received FDA approval and is extensively used for managing postoperative pain and inflammation linked to intraocular surgery.
By disease, seasonal allergic conjunctivitis (SAC) was the highest revenue-grossing segment in the global allergic conjunctivitis market in 2023 owing to the growing prevalence of seasonal allergic conjunctivitis and rising focus on development of novel drugs. For instance, in April 2023, Aldeyra Therapeutics, Inc., has reported the successful enrollment of participants in the Phase 3 INVIGORATE-2 clinical trial, which is evaluating the use of topical ocular Reproxalap-an innovative investigational new drug candidate-for treating allergic conjunctivitis. Additionally, perennial allergic conjunctivitis (PAC) is predicted to grow at fastest CAGR during the forecast period owing to the surge in prevalence of perennial allergic conjunctivitis and increasing launch of new drugs.
By dosage, with preservatives was the highest revenue-grossing segment in the global allergic conjunctivitis market in 2023 as these preservatives are essential for maintaining the sterility of eye drops, and growing demand to inhibit bacterial growth. Additionally, preservative free is predicted to grow at fastest CAGR during the forecast period owing to the increasing adoption in multi-dose eye drops and growing number of clinical trial procedures. For instance, in March 2022, The first pivotal phase 3 trial, BRIO-I, has been launched by Visus Therapeutics Inc. as part of a two-phase study that also includes BRIO-II. These trials are conducted to evaluate their primary asset, BRIMOCHOL PF, which is a preservative-free ophthalmic solution designed to treat presbyopia.
By distribution channel, drug stores & retail pharmacies was the highest revenue-grossing segment in the global allergic conjunctivitis market in 2023 owing to increasing preference by consumers and rising focus on development of new drugs. For instance, in April 2023, Nicox SA has revealed that its exclusive Chinese collaborator, Ocumension Therapeutics, has filed a new drug application (NDA) seeking approval for the distribution of Zerviate (cetirizine ophthalmic solution), 0.24%, in China. This application pertains to the use of Zerviate in treating ocular itching linked to allergic conjunctivitis. Additionally, online providers is predicted to grow at fastest CAGR during the forecast period owing to a widely favored method for buying medications and easy accessibility.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising prevalence of ocular disorders in children, increasing approvals of new drugs, and growing research & development activities. For instance, in July 2023, Harrow has announced the successful transfer of the New Drug Application (NDA) for moxifloxacin hydrochloride ophthalmic solution 0.5% (previously known as Vigamox). This transfer enables the drug to be commercially accessible in the United States under the Harrow brand name. Vigamox is an antibiotic eye drop belonging to the fluoroquinolone class and is utilized for treating bacterial conjunctivitis caused by susceptible strains of bacteria. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the surge in patient population, increasing development of healthcare infrastructure, growing investment in research projects, and rising approvals by regulatory bodies. For instance, in March 2022, Johnson & Johnson Vision Care, Inc., has disclosed that the U.S. Food and Drug Administration (FDA) has granted approval for ACUVUE Theravision with Ketotifen. Ketotifen is a widely recognized antihistamine. ACUVUE Theravision with Ketotifen represents the first product in an entirely novel category of contact lenses and offers a fresh wearing experience for contact lens users dealing with allergic eye itch.
Surge in number of clinical trial procedures is predicted to boost the market growth during the forecast period. Allergic conjunctivitis is a condition characterized by eye irritation resulting from an allergic reaction to substances like pollen or mold spores. It is particularly prevalent during the hay fever season when exposure to allergens is heightened. Allergy-related conjunctivitis is a widespread issue, particularly among individuals with allergies. As a result, pharmaceutical companies are prioritizing the development of innovative medications to address this condition. For instance, in July 2022, A groundbreaking therapy, potentially the first of its kind, developed by Aldeyra Therapeutics called Reproxalap, submitted for FDA approval, offering a new approach to treating dry eye disease. Reproxalap is designed to modulate RASP, a novel anti-inflammatory target for dry eye.
By treatment, antihistamines and mast cell stabilizers was the highest revenue-grossing segment in the global allergic conjunctivitis market in 2023 owing to the growing prevalence of allergic conjunctivitis, rising demand for antihistamine eye drops to relieve symptoms in the eyes, and increasing new product launches by market players. Additionally, corticosteroids is predicted to grow at fastest CAGR during the forecast period owing to the surge in research & development activities and rising approvals by regulatory bodies. For instance, in May 2022, Dextenza, also known as the dexamethasone punctal insert, has received FDA approval and is extensively used for managing postoperative pain and inflammation linked to intraocular surgery.
By disease, seasonal allergic conjunctivitis (SAC) was the highest revenue-grossing segment in the global allergic conjunctivitis market in 2023 owing to the growing prevalence of seasonal allergic conjunctivitis and rising focus on development of novel drugs. For instance, in April 2023, Aldeyra Therapeutics, Inc., has reported the successful enrollment of participants in the Phase 3 INVIGORATE-2 clinical trial, which is evaluating the use of topical ocular Reproxalap-an innovative investigational new drug candidate-for treating allergic conjunctivitis. Additionally, perennial allergic conjunctivitis (PAC) is predicted to grow at fastest CAGR during the forecast period owing to the surge in prevalence of perennial allergic conjunctivitis and increasing launch of new drugs.
By dosage, with preservatives was the highest revenue-grossing segment in the global allergic conjunctivitis market in 2023 as these preservatives are essential for maintaining the sterility of eye drops, and growing demand to inhibit bacterial growth. Additionally, preservative free is predicted to grow at fastest CAGR during the forecast period owing to the increasing adoption in multi-dose eye drops and growing number of clinical trial procedures. For instance, in March 2022, The first pivotal phase 3 trial, BRIO-I, has been launched by Visus Therapeutics Inc. as part of a two-phase study that also includes BRIO-II. These trials are conducted to evaluate their primary asset, BRIMOCHOL PF, which is a preservative-free ophthalmic solution designed to treat presbyopia.
By distribution channel, drug stores & retail pharmacies was the highest revenue-grossing segment in the global allergic conjunctivitis market in 2023 owing to increasing preference by consumers and rising focus on development of new drugs. For instance, in April 2023, Nicox SA has revealed that its exclusive Chinese collaborator, Ocumension Therapeutics, has filed a new drug application (NDA) seeking approval for the distribution of Zerviate (cetirizine ophthalmic solution), 0.24%, in China. This application pertains to the use of Zerviate in treating ocular itching linked to allergic conjunctivitis. Additionally, online providers is predicted to grow at fastest CAGR during the forecast period owing to a widely favored method for buying medications and easy accessibility.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising prevalence of ocular disorders in children, increasing approvals of new drugs, and growing research & development activities. For instance, in July 2023, Harrow has announced the successful transfer of the New Drug Application (NDA) for moxifloxacin hydrochloride ophthalmic solution 0.5% (previously known as Vigamox). This transfer enables the drug to be commercially accessible in the United States under the Harrow brand name. Vigamox is an antibiotic eye drop belonging to the fluoroquinolone class and is utilized for treating bacterial conjunctivitis caused by susceptible strains of bacteria. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the surge in patient population, increasing development of healthcare infrastructure, growing investment in research projects, and rising approvals by regulatory bodies. For instance, in March 2022, Johnson & Johnson Vision Care, Inc., has disclosed that the U.S. Food and Drug Administration (FDA) has granted approval for ACUVUE Theravision with Ketotifen. Ketotifen is a widely recognized antihistamine. ACUVUE Theravision with Ketotifen represents the first product in an entirely novel category of contact lenses and offers a fresh wearing experience for contact lens users dealing with allergic eye itch.
Segmentation: Allergic Conjunctivitis Market Report 2023 - 2034
Allergic Conjunctivitis Market Analysis & Forecast by Treatment 2023 - 2034 (Revenue USD Bn)
- Corticosteroids
- Antihistamines and Mast Cell Stabilizers
- Others
Allergic Conjunctivitis Market Analysis & Forecast by Disease 2023 - 2034 (Revenue USD Bn)
- Perennial Allergic Conjunctivitis (PAC)
- Seasonal Allergic Conjunctivitis (SAC)
Allergic Conjunctivitis Market Analysis & Forecast by Dosage 2023 - 2034 (Revenue USD Bn)
- Preservative Free
- With Preservative
Allergic Conjunctivitis Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Drug Store & Retail Pharmacies
- Hospital Pharmacies
- Online Providers
Allergic Conjunctivitis Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Allergic Conjunctivitis Market: Treatment Estimates & Trend Analysis
8. Allergic Conjunctivitis Market: Disease Estimates & Trend Analysis
9. Allergic Conjunctivitis Market: Dosage Estimates & Trend Analysis
10. Allergic Conjunctivitis Market: Distribution Channel Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Allergic Conjunctivitis Market
13. Europe Global Allergic Conjunctivitis Market
14. Asia Pacific Global Allergic Conjunctivitis Market
15. Latin America Global Allergic Conjunctivitis Market
16. MEA Global Allergic Conjunctivitis Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Johnson & Johnson Services Inc.
- Ajanta Pharma Limited
- Santen Pharmaceuticals Co. Ltd.
- Alembic Pharmaceuticals Ltd
- Cipla Inc.
- AbbVie Inc
- Indoco Remedies Ltd.
- Novartis AG
- Bausch Health Companies Inc.
- Sun Pharmaceuticals Industries Ltd.
- Spectra Vision Care Pvt. Ltd.
- Teva Pharmaceutical Industries Ltd.
- Grevis Pharmaceutical Private Limited
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 3.85 Billion |
| Forecasted Market Value ( USD | $ 7.61 Billion |
| Compound Annual Growth Rate | 6.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 13 |
